AJAdelle S. Jee

Adelle S. Jee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adelle S. Jee has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Tamera J. Corte

    Department of Respiratory Medicine Royal Prince Alfred Hospital, School of Medicine, University of Sydney Faculty of Medicine and Health, and Australia National Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis Sydney New South Wales Australia

    5 shared publications
  • Jane F. Bleasel

    School of Medicine and Public Health, Faculty of Health Medicine and Wellbeing The University of Newcastle Callaghan New South Wales Australia

    4 shared publications
  • Stephen Adelstein

    School of Medicine, University of Sydney Faculty of Medicine and Health, and Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, and Central Immunopathology Laboratory, NSW Health Pathology New South Wales Australia

    4 shared publications
  • Joanne Sahhar

    Department of Inflammatory Diseases, Monash Health, Melbourne, Victoria, Australia, and Department of Medicine, Monash University, Department of Rheumatology Clayton Victoria Australia

    3 shared publications
  • Lauren K. Troy

    Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

    3 shared publications
  • Donna Lai

    Bosch Institute, Molecular Biology Facility University of Sydney Sydney New South Wales Australia

    2 shared publications

Latest Publications

  • Fibrotic Morphology and Survival in Interstitial Pneumonia with Autoimmune Features

    by Adelle S. Jee, Janelle Vu Pugashetti, Leda Yazbeck, Andrew Curnow, Cathryn T. Lee, Andrew Yu, Noor Hammoud, Gabrielle Y. Liu, Jennifer M. Wang, Evelyn Lynn, et al.

    Application of the 2015 Interstitial Pneumonia with Autoimmune Features (IPAF) research statement produced IPAF cohorts with favorable transplant-free survival (TFS) relative to the idiopathic interstitial pneumonia (IP) base populations from which they arose. Whether differences in underlying fibrotic morphology may explain this observation remains unclear. A multi-centre retrospective cohort study was performed. IPAF criteria were applied to six idiopathic IP cohorts from the US and UK using available clinical data. Fibrotic morphology was determined in separate analyses using imaging and histopathological data. Three-year TFS was compared between cohorts before and after adjustment for fibrotic morphology. Stratified analyses were performed to assess the prognostic significance of IPAF classification and presence clinical and serological domain features within key morphological groups. Outcomes were benchmarked against a connective tissue disease-associated (CTD-ILD) reference cohort (n=1566). Of 5042 individuals with idiopathic IP included in the analysis, 649 (12.9%) met IPAF criteria. Whilst IPAF classification was associated with favorable TFS before adjustment for imaging-based fibrotic morphology (HR 0.79; 95% CI 0.68–0.92; p=0.003), this association was attenuated after adjustment (HR 0.91; 95% CI 0.77–1.07; p=0.25). Results were similar when adjusting for histopathological-based morphology. IPAF classification had no prognostic significance within common morphological groups, but the presence of IPAF clinical domain features captured a phenotype with CTD-ILD-like natural history in the setting of non-UIP morphology. After accounting for differences in fibrotic morphology, IPAF classification has no prognostic significance relative to the idiopathic IP base population, suggesting that the current IPAF construct may not effectively identify a unique population.

  • Disease Behaviour Classification: A pragmatic model for predicting outcomes in Interstitial Lung Disease

    by Megan Harrison, Helen E. Jo, Lauren K. Troy, Benjamin Nguyen, Susanne E. Webster, Monika Geis, Simon Lai, Ellie Mulyadi, Wendy A. Cooper, Annabelle Mahar, et al.


  • Open Access

    A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis–Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study

    by Adelle S. Jee, Iain Stewart, Peter Youssef, Stephen Adelstein, Donna Lai, Sheng Hua, Wendy Stevens, Susanna Proudman, Gene‐Siew Ngian, Ian N. Glaspole, et al.

    Objective: In patients with systemic sclerosis (SSc), we investigated composite serum biomarker panels for the diagnosis and risk stratification of SSc–associated interstitial lung disease (SSc‐ILD).Methods: We analyzed 28 biomarkers in 640 participants: 259 patients with SSc‐ILD and 179 SSc patients without ILD (Australian Scleroderma Cohort Study), 172 patients with idiopathic pulmonary fibrosis (IPF‐controls) (Australian IPF Registry), and 30 healthy controls. A composite index was developed from biomarkers associated with ILD in multivariable analysis derived at empirical thresholds. We evaluated the performance of the index to identify ILD, and specifically SSc‐ILD, and its association with lung function, disease extent on radiography, and patient health–related quality of life in derivation and validation cohorts. Biomarkers to distinguish SSc‐ILD from IPF‐controls were identified.Results: A composite biomarker index, comprising surfactant protein D (SP‐D), Ca15‐3, and intercellular adhesion molecule 1 (ICAM‐1), was strongly associated with SSc‐ILD diagnosis, independent of age, sex, smoking history, and lung function (for biomarker index score 3, pooled adjusted odds ratio was 12.72 (95% confidence interval 4.59–35.21) (P < 0.001). The composite index strengthened the performance of individual biomarkers for SSc‐ILD identification. In SSc patients, a higher index was associated with worse baseline disease severity (for biomarker index score 3 relative to biomarker index score 0, the adjusted absolute change in forced vital capacity percent predicted was −17.84% and the diffusing capacity for carbon monoxide percent predicted was −20.16%; both P < 0.001).Conclusion: A composite serum biomarker index, comprising SP‐D, Ca15‐3, and ICAM‐1, may improve the identification and risk stratification of ILD in SSc patients at baseline.


  • Open Access

    Delays in idiopathic pulmonary fibrosis diagnosis and treatment: Time for change

    by Adelle S. Jee, Felix Chua

    See related article


  • Diagnosis of myositis-associated interstitial lung disease: Utility of the myositis autoantibody line immunoassay

    by Adelle S. Jee, Matthew J.S. Parker, Jane F. Bleasel, Lauren K. Troy, Edmund M. Lau, Helen E. Jo, Alan K.Y. Teoh, Susanne Webster, Stephen Adelstein, Tamera J. Corte


  • Open Access

    Nailfold capillaroscopy by smartphone-dermatoscope for connective tissue disease diagnosis in interstitial lung disease: a prospective observational study

    by Adelle S. Jee, Matthew J.S. Parker, Neil McGill, Jane F. Bleasel, Susanne Webster, Lauren K. Troy, Tamera J. Corte

    Nailfold capillaroscopy (NFC) is a non-invasive tool validated for systemic sclerosis diagnosis. The role and interpretation of NFC in interstitial lung disease (ILD) patients for the diagnosis of connective tissue disease associated ILD (CTD-ILD) remains undefined.In a prospective study, quantitative and qualitative NFC by smartphone-dermatoscope (3M Dermlite-DL4ΤΜ attached to iPhone-6plusΤΜ) was performed in 96 patients with well-defined CTD-ILD (n=27) and non-CTD ILD (n=69; idiopathic interstitial pneumonia n=42, interstitial pneumonia with autoimmune features n=27) by ILD-multidisciplinary meeting. NFC scoring was performed by two independent, blinded specialist rheumatologists. Comprehensive baseline clinical, serological, physiological and radiological data were included. Multivariable models for CTD diagnosis in ILD, comprising nailfold characteristics at empirical thresholds determined by receiver operating characteristic curve analysis and clinical variables, were explored.In 94 patients with complete NFC data (total 687 images, median eight images per patient from eight digits), low capillary density (<6 capillaries/millimetre), increased giant capillaries (≥3), avascular areas (≥2) and microhaemorrhages all strongly enhanced the discrimination of CTD-ILD from non-CTD ILD (OR 5.00–7.47) independent of clinical covariates. In multivariable analysis, low capillary density and microhaemorrhages were independent predictors of CTD in ILD additional to the risk conferred by serology and radiology. Microhaemorrhages were also a strong predictor of CTD (adjusted OR 13.45, p=0.006) independent of clinical manifestations. All pre-specified qualitative NFC classification schemes identified CTD-ILD (OR range 3.27–8.47).NFC performed by smartphone-dermatoscope is an accessible, clinically feasible tool that may improve the identification of CTD further to routine clinical assessment of the ILD patient.


  • Late Breaking Abstract - A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study

    by Adelle S. Jee, Iain Stewart, Peter Youssef, Stephen Adelstein, Donna Lai, Sheng Hua, Wendy Mr Stevens, Susanna Proudman, Gene-Siew Ngian, Ian N Glaspole, et al.

    Introduction: Systemic sclerosis associated interstitial lung disease (SSc-ILD) is a leading cause of morbidity and mortality in SSc. Precise measures to identify SSc-ILD and assist risk-stratification are lacking. Aim: Investigate composite serum biomarker panels for SSc-ILD diagnosis. Methods: 28 biomarkers were analysed in 640 participants from two national longitudinal cohorts:259 SSc-ILD, 179 SSc-controls without ILD, 172 IPF-controls, and 30 healthy controls. A composite index was developed from biomarkers associated with fibrotic lung disease in multivariable analysis derived at empirical thresholds. Performance of the index to identify fibrotic lung disease and SSc-ILD, its association with physiology, quality of life and transplant free survival (TFS) were evaluated in derivation and validation cohorts. Biomarkers to distinguish SSc-ILD from IPF-controls were identified. Results: A composite biomarker index, comprising SP-D, Ca15-3 and ICAM-1, was strongly associated with SSc-ILD diagnosis, independent of age, sex, smoking and lung function (index=3: pooled adj. OR 12·72, p<0·001). The index strengthened the performance of individual biomarkers for SSc-ILD identification. In SSc patients, a higher biomarker index was associated with worse baseline disease severity (index=3 relative to index=0: adjusted absolute change in FVC% –17·84% and DLCO% –20·16%, both p<0·001) and TFS (index=3: pooled adj. HR 2·27, p=0·043). TGF-b1 and CXCL-10 discriminated SSc-ILD from IPF. Conclusion: A composite serum biomarker index, comprising SP-D, Ca15-3, ICAM-1, may improve the identification and severity assessment of SSc-ILD at baseline.


  • Baseline Characteristics and Survival of an Australian Interstitial Pneumonia with Autoimmune Features Cohort

    by Adelle S. Jee, Matthew J.S. Parker, Jane F. Bleasel, Lauren K. Troy, Edmund M. Lau, Helen E. Jo, Alan K.Y. Teoh, Stephen Adelstein, Susanne Webster, Tamera J. Corte

    Background and objective: The research term “interstitial pneumonia with autoimmune features” (IPAF) encompasses interstitial lung disease (ILD) patients with autoimmune features not meeting diagnostic criteria for a defined connective tissue disease (CTD). It remains unclear if IPAF is a distinct disease entity with implications for management and prognosis. We describe an Australian IPAF population and compare their baseline characteristics and outcomes with distinct cohorts of idiopathic interstitial pneumonia (IIP), CTD-ILD, and unclassifiable ILD. Methods: Review of 291 consecutive patients attending a specialist ILD clinic was performed. Patients with a diagnosis of IIP, CTD-ILD, and unclassifiable ILD by ILD-multidisciplinary meeting (ILD-MDM) were included. Patients meeting the IPAF criteria were identified. Baseline clinical data, survival, and progression were compared between ILD groups. Results: 226 patients were included, 36 meeting the IPAF criteria. IPAF patients demonstrated a high prevalence of autoantibodies to tRNA synthetase (35.3%), Ro52 (27.8%), and neutrophilic cytoplasmic antigens (ANCA; 20.0%). IPAF and CTD-ILD patients demonstrated similar clinical characteristics (mean age 66.6 and 63.7 years, respectively, female predominant, frequent CTD-manifestations). Lung function did not differ between ILD groups. Disease severity, pulmonary hypertension (PH), and ILD-MDM diagnosis were strong predictors of worse transplant-free survival (TFS). Meeting the IPAF criteria was not associated with TFS. Conclusions: We identified IPAF as a heterogeneous phenotype that overlaps considerably with CTD-ILD. Disease severity, PH, and ILD-MDM diagnosis were more powerful predictors of survival outcomes than meeting the IPAF criteria.


  • Open Access

    Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*

    by Adelle S. Jee, Robert Sheehy, Peter Hopkins, Tamera J. Corte, Christopher Grainge, Lauren K. Troy, Karen Symons, Lissa M. Spencer, Paul N. Reynolds, Sally Chapman, et al.

    Pulmonary complications in CTD are common and can involve the interstitium, airways, pleura and pulmonary vasculature. ILD can occur in all CTD (CTD‐ILD), and may vary from limited, non‐progressive lung involvement, to fulminant, life‐threatening disease. Given the potential for major adverse outcomes in CTD‐ILD, accurate diagnosis, assessment and careful consideration of therapeutic intervention are a priority. Limited data are available to guide management decisions in CTD‐ILD. Autoimmune‐mediated pulmonary inflammation is considered a key pathobiological pathway in these disorders, and immunosuppressive therapy is generally regarded the cornerstone of treatment for severe and/or progressive CTD‐ILD. However, the natural history of CTD‐ILD in individual patients can be difficult to predict, and deciding who to treat, when and with what agent can be challenging. Establishing realistic therapeutic goals from both the patient and clinician perspective requires considerable expertise. The document aims to provide a framework for clinicians to aid in the assessment and management of ILD in the major CTD. A suggested approach to diagnosis and monitoring of CTD‐ILD and, where available, evidence‐based, disease‐specific approaches to treatment have been provided.


  • Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease – frontiers and horizons

    by Adelle S. Jee, Joanne Sahhar, Peter Youssef, Jane Bleasel, Stephen Adelstein, Maianh Nguyen, Tamera J. Corte